SCHEMBL6097464

SCHEMBL6097464

Cc1ccc2cc[nH]c2c1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNF P01375 1/20 0.42
RIPK1 Q13546 1/20 0.42
AHR P35869 3/20 0.40
BRD4 O60885 2/20 0.39
TAF1 P21675 1/20 0.39
BRPF1 P55201 1/20 0.39
CREBBP Q92793 1/20 0.39
CECR2 Q9BXF3 1/20 0.39
BRD9 Q9H8M2 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2A6 P11509 1/20 0.38
TSHR P16473 1/20 0.38
KEAP1 Q14145 1/20 0.35
NR3C1 P04150 2/20 0.35
PGR P06401 1/20 0.35
NR3C2 P08235 1/20 0.35
AR P10275 1/20 0.35
PDPK1 O15530 1/20 0.34
PIM3 Q86V86 1/20 0.33
DAO P14920 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29713816 1.00 TNF (0.42) TNFRIPK1AHRBRD4TAF1
SCHEMBL10464399 0.83 TSHR (0.42) TNFRIPK1AHRBRD4TAF1
SCHEMBL31711384 0.80 CYP1A2 (0.34) CYP1A2CYP2A6TSHRDAO
SCHEMBL16091101 0.79 TNF (0.50) TNFRIPK1AHRBRD4TAF1
SCHEMBL5580913 0.79 MAPT (0.52) TNFRIPK1AHRBRD4TAF1
SCHEMBL25079005 0.77 TNF (0.39) TNFRIPK1AHRBRD4TAF1
SCHEMBL17659438 0.77 AHR (0.52) TNFRIPK1AHRBRD4TAF1
SCHEMBL18966966 0.77 TNF (0.59) TNFRIPK1AHRBRD4TAF1
SCHEMBL24373440 0.77 TNF (0.39) TNFRIPK1AHRBRD4TAF1
SCHEMBL917801 0.77 TNF (0.39) TNFRIPK1AHRBRD4TAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108473526-B Process for producing oligonucleotide and nucleoside, nucleotide or oligonucleotide 味之素株式会社 2022-08-09 CN claimed
CN-113045724-B Phosphonic acid water reducing agent containing indole skeleton structure, and preparation method and application thereof 江苏苏博特新材料股份有限公司 2022-07-08 CN claimed
CN-113045724-A Phosphonic acid water reducing agent containing indole skeleton structure, and preparation method and application thereof 江苏苏博特新材料股份有限公司 2021-06-29 CN claimed
US-10919928-B2 Oligonucleotide production method, and nucleoside, nucleotide, or oligonucleotide AJINOMOTO CO., INC. (JP) 2021-02-16 US claimed
EP-3398955-A1 OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE AJINOMOTO CO., INC. (JP) 2018-11-07 EP claimed
US-20180282365-A1 OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE AJINOMOTO CO., INC. (JP) 2018-10-04 US claimed
CN-108473526-A Process for producing oligonucleotide and nucleoside, nucleotide or oligonucleotide 味之素株式会社 2018-08-31 CN claimed
EP-2711370-B1 METHOD FOR PRODUCING OLIGONUCLEOTIDES AJINOMOTO KK (JP) 2018-01-03 EP claimed
US-9029528-B2 Solution-based method of making oligonucleotides via phosphoramidite coupling AJINOMOTO CO., INC. (JP) 2015-05-12 US claimed
EP-2711370-A1 METHOD FOR PRODUCING OLIGONUCLEOTIDE Ajinomoto Co., Inc. (JP) 2014-03-26 EP claimed
CN-103476784-A Method for producing oligonucleotide AJINOMOTO KK 2013-12-25 CN claimed
US-20120296074-A1 PRODUCTION METHOD OF OLIGONUCLEOTIDE AJINOMOTO CO., INC. (JP) 2012-11-22 US claimed
EP-4741411-A2 OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE AJINOMOTO CO., INC. (JP) 2026-05-13 EP disclosed
EP-4695265-A1 METHOD AND COMPOSITION FOR OLIGONUCLEOTIDE SYNTHESIS Bachem Holding AG (CH) 2026-02-18 EP disclosed
EP-4678626-A1 LONG-CHAIN ALKENYLOXY-SUBSTITUTED BENZOYL DERIVATIVE AND OLIGONUCLEOTIDE SYNTHESIS METHOD USING SAME Spera Pharma, Inc. (JP) 2026-01-14 EP disclosed
EP-4605403-B1 METHOD AND COMPOSITION FOR OLIGONUCLEOTIDE SYNTHESIS BACHEM HOLDING AG (CH) 2025-11-26 EP disclosed
US-7057052-B2 Heterocyclic quinones as pharmaceutical agents DUKE UNIVERSITY (US) 2006-06-06 US disclosed
US-5736534-A HYPERPROLIFERATIVE DISEASES; INHIBITORS OF PROTEIN-TYROSINE KINASES SUCH AS EPIDERMAL GROWTH FACTOR RECEPTOR; BRAIN, LUNG, BREAST CANCER; PSORIASIS AND BENIGN PROSTATE HYPERPLASIA PFIZER INC. (US) 1998-04-07 US disclosed
EP-0746554-A1 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS PFIZER INC. (US) 1996-12-11 EP disclosed
WO-1995023141-A1 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS PFIZER INC. (US) 1995-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180282365-A1 OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE NUDT1, RNGTT, POLN TNF 2859/4885RIPK1 2721/4885AHR 4106/4885
US-10919928-B2 Oligonucleotide production method, and nucleoside, nucleotide, or oligonucleotide POLL, POLM, NUDT1 TNF 2272/4885RIPK1 2104/4885AHR 4673/4885
US-20120296074-A1 PRODUCTION METHOD OF OLIGONUCLEOTIDE RNGTT, POLM, RNMT TNF 3340/4885RIPK1 4360/4885AHR 3968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.